NCM
Nantahala Capital Management’s Keros Therapeutics KROS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.6M | Buy |
1,620,692
+113,902
| +8% | +$1.52M | 0.85% | 16 |
|
|
2025
Q1 | $15.4M | Buy |
1,506,790
+591,742
| +65% | +$6.03M | 0.61% | 17 |
|
|
2024
Q4 | $14.5M | Buy |
915,048
+533,389
| +140% | +$8.44M | 0.62% | 30 |
|
|
2024
Q3 | $22.2M | Buy |
381,659
+2,852
| +0.8% | +$166K | 1.12% | 12 |
|
|
2024
Q2 | $17.3M | Buy |
378,807
+84,810
| +29% | +$3.88M | 1.01% | 12 |
|
|
2024
Q1 | $19.5M | Sell |
293,997
-16,144
| -5% | -$1.07M | 1.11% | 12 |
|
|
2023
Q4 | $12.3M | Sell |
310,141
-18,640
| -6% | -$741K | 0.74% | 21 |
|
|
2023
Q3 | $10.5M | Sell |
328,781
-168,380
| -34% | -$5.37M | 0.9% | 20 |
|
|
2023
Q2 | $20M | Sell |
497,161
-245,658
| -33% | -$9.87M | 1.93% | 9 |
|
|
2023
Q1 | $31.7M | Sell |
742,819
-49,274
| -6% | -$2.1M | 2.43% | 9 |
|
|
2022
Q4 | $38M | Sell |
792,093
-53,599
| -6% | -$2.57M | 2.47% | 8 |
|
|
2022
Q3 | $31.8M | Sell |
845,692
-66,209
| -7% | -$2.49M | 2.06% | 9 |
|
|
2022
Q2 | $25.2M | Buy |
911,901
+95,071
| +12% | +$2.63M | 1.26% | 16 |
|
|
2022
Q1 | $44.4M | Buy |
816,830
+20,132
| +3% | +$1.09M | 1.97% | 12 |
|
|
2021
Q4 | $46.6M | Buy |
796,698
+36,315
| +5% | +$2.12M | 1.64% | 11 |
|
|
2021
Q3 | $30.1M | Buy |
760,383
+161,503
| +27% | +$6.39M | 0.95% | 18 |
|
|
2021
Q2 | $25.4M | Buy |
598,880
+138,508
| +30% | +$5.88M | 0.72% | 23 |
|
|
2021
Q1 | $28.3M | Sell |
460,372
-74,142
| -14% | -$4.56M | 0.83% | 21 |
|
|
2020
Q4 | $37.7M | Buy |
534,514
+257,687
| +93% | +$18.2M | 1.17% | 15 |
|
|
2020
Q3 | $10.7M | Buy |
276,827
+1,827
| +0.7% | +$70.5K | 0.33% | 51 |
|
|
2020
Q2 | $10.3M | Buy |
+275,000
| New | +$10.3M | 0.31% | 45 |
|